Bulletin from the extraordinary general meeting and second control meeting in Asarina Pharma
On 22 April 2025, Asarina Pharma AB (publ) (the “Company”) held an extraordinary general meeting and second control meeting, at which the shareholders resolved that the Company would enter into voluntary liquidation.
Presentation of the second control balance sheet
At the extraordinary general meeting, the second control balance sheet as of 31 March 2025 was presented, along with the auditor’s statement thereon and the documents referred to in Chapter 25, Section 4 of the Swedish Companies Act, evidencing that the Company’s equity had been restored.
Resolution on voluntary liquidation
The extraordinary general meeting resolved in accordance with the board of directors’ proposal that the Company shall enter into voluntary liquidation in accordance with Chapter 25, Section 3 of the Swedish Companies Act. The resolution on liquidation is proposed to take effect on 1 July 2025, such that the board and the management can conduct the annual general meeting before the Company enters liquidation. The distribution of any liquidation proceeds is expected to take place at the latest in connection with the presentation of the liquidator’s final report. Attorney Johan Klåvus, Trägårdh Advokatbyrå, has been proposed as liquidator.
For further information, please contact:
Paul De Potocki, Chairman of the Board of Directors
Phone: +46 (70) 669 9618
E-mail: paul.depotocki@telia.com
Jakob Dynnes Hansen, CFO
Phone: +45 5132 3698
E-mail: jakob.dynnes@asarinapharma.com
Kommuniké från extra bolagsstämma tillika andra kontrollstämma i Asarina Pharma
Den 22 april 2025 höll Asarina Pharma AB (publ) (”Bolaget”) extra bolagsstämma tillika andra kontrollstämma, varvid aktieägarna beslutade att Bolaget ska träda i frivillig likvidation.
Framläggande av andra kontrollbalansräkningen
Vid stämman framlades den andra kontrollbalansräkning per den 31 mars 2025 och revisorns yttrande över kontrollbalansräkningen samt handlingar enligt 25 kap. 4 § aktiebolagslagen som visade att Bolagets egna kapital är återställt.
Beslut om frivillig likvidation
Den extra bolagsstämman beslutade i enlighet med styrelsens förslag att Bolaget ska träda i frivillig likvidation i enlighet med 25 kap. 3 § aktiebolagslagen. Beslutet om likvidation föreslås träda i kraft den 1 juli 2025, vilket tillåter styrelsen och ledningen att hålla årsstämma innan Bolaget träder i likvidation. Skifte av eventuell likvidationslikvid förväntas ske senast i samband med framläggandet av likvidatorns slutredovisning. Till likvidator föreslås advokat Johan Klåvus, Trägårdh Advokatbyrå.
För mer information, vänligen kontakta:
Paul De Potocki, styrelseordförande
Telefon: +46 (70) 669 9618
E-post: paul.depotocki@telia.com
Jakob Dynnes Hansen, CFO
Telefon: +45 5132 3698
E-post: jakob.dynnes@asarinapharma.com
SEPRANOLONE & MENSTRUAL MIGRAINE
POSITIVE PHASE II A RESULTS FOR SEPRANOLONE IN TOURETTE SYNDROME
“I can easily see Sepranolone becoming the new first-line treatment for Tourette patients who require pharmaceutical treatment. I believe Sepranolone has a strong future.”
Consultant neurologist Dr Heidi Biernat Bispebjerg University Hospital CopenhagenRead about the results here.
On April 1, 2023 Asarina Pharma released positive results for its Phase IIa clinical study of Sepranolone in Tourette Syndrome. Clinical Neurologist Dr Heidi Biernat, Head of the Tourette Syndrome Clinic at Bispebjerg University Hospital in Copenhagen, ran the Study. Read her thoughts on the challenges of today’s TS treatments, the patient response to Sepranolone and how she sees its potential as a first-choice treatment for pharmaceutical intervention in Tourette Syndrome.
SEPRANOLONE
“I believe Sepranolone will always attract interest from clinicians and patients, whatever indication it is launched for.”
Professor Marie Bixo, University of UmeåThe neurochemical GABA is the brain’s most powerful inhibitory neurotransmitter. It plays a crucial role in inhibiting and reducing stress, fear and anxiety levels. But what keeps GABA in check? The neurosteroid Allopregnanolone (or ALLO) is a potent modulator of GABA, acting on the GABA-A receptor, a major pathway for GABA within the brain.
The body’s endogenous compound—Sepranolone—regulates and modulates the negative effects of ALLO. Asarina Pharma is the first company to have developed and synthesized Sepranolone as a medication, patenting a pharmaceutical formulation in 2010.
Sepranolone has achieved an excellent safety profile in substantial clinical trials. It was tested in a Phase IIa Tourette syndrome study in 2022, with topline results expected at the end of March 2023.
TOURETTE SYNDROME
“I believe we are on the crest of a new wave of understanding of just how broad the impact of Allopregnanolone really is. Compulsivity impacts on so many different conditions, from ADHD and OCD/B through to eating disorders and addiction.”
Assoc prof Marco Bortolato, University of Utah
Tourette syndrome is a cruel condition typically striking first between the ages of 3 – 9 years old. Yet many current treatments, like the anti-psychotic Haldol, have severe side effects ranging from blurred vision, nausea and diarrhoea to involuntary movement disorder, irregular heartbeat and even renal failure.
Sepranolone: A safer approach
In May 2019 Asarina Pharma demonstrated in a preclinical animal study that Sepranolone reduced tics on a par with Haldol, without inducing any motor side effects.
Asarina Pharma CEO Peter Nordkild: “This is a new approach, and a safe one. There are no neurosteroid-based medications currently being used to treat TS. A positive result would be extremely promising for patients, and indicate that Sepranolone could potentially play a part in treating a range of other ALLO-related stress disorders.”
OBSESSIVE-COMPULSIVE DISORDER
“OCD ‘turns dust into dynamite’ they say, it’s true for me. Even though I tell myself ‘this isn’t me, it’s the OCD’, the heaviness, the panic, can be totally overwhelming”
‘Helena’ 24, Sweden.
OCD strikes as many as 12 in every 1,000 people (1.2% of the population), with slightly more women than men affected. The impact can be devastating – with a disproportionately high number of OCD cases, about 50%, classified as severe, and less than a quarter classed as mild (OCD UK).
Lack of pharmaceutical treatment options
Yet despite its prevalence and impact, treatment options, particularly pharmaceutical ones, leave many needs unmet. ERP (exposure and response therapy), today’s front-line treatment, can work well, but is demandingand time-consuming. Relapse is common. Meanwhile, SSRIs, today’s most commonly prescribed pharma treatment, have an overall efficacy of < 50%.
Asarina Pharma’s safe, endogenous compound Sepranolone represents a new approach to treating OCD.